Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Labcorp Holdings Inc. amended its receivables purchase agreement on January 28, 2026, extending the scheduled termination date of its receivables facility to January 26, 2029. The facility continues to provide funding backed by accounts receivable through Labcorp Receivables LLC.
The amendment adds a committed $125 million accordion feature, allowing Labcorp Receivables to increase the facility limit from $700 million to up to $825 million at its option on or before May 29, 2026, and removes a prior 0.10% SOFR yield adjustment. Labcorp Receivables remains a separate legal entity whose creditors have first claim on its assets, with excess collections potentially remitted to Labcorp.
Labcorp Holdings Inc. reported that it plans to release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast at 9 a.m. ET that same day to review and discuss the results with investors and analysts. The earnings press release and detailed financial information will be made available on the Labcorp Investor Relations website, giving shareholders and other interested parties direct access to the figures and commentary.
Labcorp Holdings Inc. declared a cash dividend of $0.72 per share of common stock. The dividend will be paid on March 12, 2026 to shareholders who are on record as of the close of business on February 27, 2026. This payment reflects the company’s ongoing practice of returning cash to its stockholders through regular dividends.
Labcorp Holdings Inc. executive Jonathan C. Meltzer reported his initial equity holdings in the company. As EVP, Operations of Labcorp Holdings Inc. (LH), he directly holds 2,518.3256 shares of common stock. He also holds several grants of restricted stock units, each representing the contingent right to receive one share of common stock.
These restricted stock units cover 263 shares vesting on February 7, 2026, 534 shares vesting in two equal installments on February 6, 2026 and February 6, 2027, 730 shares vesting in three equal annual installments beginning February 11, 2026, and 1,320 shares vesting in three equal annual installments beginning December 1, 2026. All holdings are reported as directly owned by Meltzer.
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reports her beneficial ownership of company securities. She directly holds 3,052.4574 shares of Labcorp common stock. In addition, she holds several grants of Restricted Stock Units (RSUs), each representing the contingent right to receive one share of Labcorp common stock.
The RSUs cover 178 shares vesting on February 7, 2026; 360 shares vesting in two equal installments on February 6, 2026 and February 6, 2027; 650 shares vesting in three equal annual installments beginning on February 11, 2026; and 770 shares vesting in three equal annual installments beginning on July 1, 2026. All holdings are reported as directly owned.
Labcorp Holdings Inc. executive Bryan T. Vaughn, EVP, Diagnostics, reported his initial equity holdings in the company. He directly beneficially owns 5,146.5702 shares of Labcorp common stock. He also holds several blocks of restricted stock units (RSUs), each representing the right to receive one share of common stock if vesting conditions are met.
These RSUs cover 178 shares vesting on February 7, 2026, 500 shares vesting on November 1, 2026, 360 shares vesting in two equal installments on February 6, 2026 and February 6, 2027, and 654 shares vesting in two equal installments on July 1, 2026 and July 1, 2027. Additional RSUs for 970 and 1,320 shares vest in three equal annual installments beginning February 11, 2026 and December 1, 2026, respectively.
Labcorp Holdings Inc. reported that it will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference. The session is scheduled for Tuesday, January 13 at 4:30 p.m. (PT) and will feature company representatives discussing Labcorp’s business with investors and industry participants.
The company will provide a live audio webcast of the fireside chat through its investor relations website at ir.Labcorp.com, and the recording will be archived for replay. Labcorp also furnished a press release dated December 30, 2025 as an exhibit, formally announcing its conference participation.
Labcorp Holdings Inc. reports that Mark Schroeder, its Executive Vice President, President, Diagnostics Laboratories and Chief Operations Officer, has notified the company of his intention to retire.
His retirement is expected to be effective on April 1, 2026, giving the company time to manage the transition of responsibilities across its diagnostics laboratories operations and broader executive team.
Labcorp Holdings Inc. reported that board member Dr. D. Gary Gilliland has decided to retire from its Board of Directors. The company received his notice on December 5, 2025, and his retirement will be effective December 31, 2025. Labcorp later issued a press release on December 10, 2025 to publicly announce his upcoming departure, and that release is included as an exhibit to this report.
Labcorp Holdings Inc. director Victor Bulto Carulla reported a new equity award in the form of restricted stock units. On December 1, 2025, he received 136 Restricted Stock Units, each representing the right to receive one share of Labcorp Holdings Inc. common stock. The award was reported as directly owned.
The Restricted Stock Units are scheduled to vest fully on December 1, 2026, meaning the shares underlying the award become deliverable on that date, subject to the award’s usual conditions. This filing is a routine disclosure of director equity compensation and does not involve any open‑market purchase or sale of shares.